rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ARTL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Artelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial Results
      Nov 12Yahoo FinanceARTL
      Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
      Oct 29Yahoo FinanceARTL
      Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
      Oct 26Yahoo FinanceARTL
      Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
      Oct 7Yahoo FinanceARTL
      Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening? - Artelo Biosciences (NASDAQ:ARTL)

      Artelo Biosciences, Inc. (NASDAQ: ARTL) shares are surging Wednesday afternoon after the clinical-stage biopharmaceutical company announced the filing of a new provisional patent application covering its drug candidate ART27.13 for the treatment of obesity.

      Sep 23BenzingaARTL
      12 Health Care Stocks Moving In Wednesday's Intraday Session - Artelo Biosciences (NASDAQ:ARTL), Vistagen

      Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics (NASDAQ:VTGN) shares

      Sep 23BenzingaADGMARTLJAGXVTGN
      Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

      As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks Application expands Artelo’s intellectual property position for ART27.13 into obesity, where J.P. Morgan has projected the global GLP-1 market could reach $200 billion by 2030 New findings show the combination further improved oral glucose tolerance and increased bone mineral density, an effect not observed in

      Sep 23Yahoo FinanceARTL
      Artelo files patent application for obesity treatment ART27.13
      Sep 23Investing.comARTL
      Artelo Cannabinoid Drug Doubles Weight Loss When Paired with Popular Obesity Drug
      Sep 16BenzingaARTL
      Artelo’s ART27.13 matches semaglutide weight loss in mice study
      Sep 16Investing.comARTL
      Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

      Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic® and Wegovy® Combining ART27.13 with semaglutide produced approximately 40% weight loss – double that of semaglutide alone Results indicate that ART27.13 may possess the profile of a “metabolic regulator” capable of differentially modifying body weight and other parameters depending on the metabolic phenotype being treated SOLANA B

      Sep 16Yahoo FinanceARTL
      Artelo Biosciences at H.C. Wainwright: early data, tight cash
      Sep 11Investing.comARTL
      Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      SOLANA BEACH, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that Gregory D. Gorgas, CEO of Artelo Biosciences, will be participating in the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026

      Sep 8Yahoo FinanceARTL
      Artelo Biosciences announces 1-for-9 reverse stock split
      Aug 27Investing.comARTL
      Artelo Biosciences Announces Reverse Stock Split

      Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026SOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced a 1-for-9 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock

      Aug 27Yahoo FinanceARTL

      This is the newest page. Registered accounts read further back.